Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5149 | 177073-44-8 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Choriogonadotropin alfa, is an analogue of Luteinizing Hormone (LH) and binds to the LH/hCG receptor of the granulosa and theca cells of the ovary to effect these changes in the absence of an endogenous LH surge. In pregnancy, hCG, secreted by the placenta, maintains the viability of the corpus luteum to provide the continued secretion of estrogen and progesterone necessary to support the first trimester of pregnancy.
|
| Dose | Unit | Route |
|---|---|---|
| 0.25 | mg | P |
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 20, 2000 | FDA | EMD SERONO |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ovarian hyperstimulation syndrome | 7187.42 | 47.32 | 1012 | 4243 | 4850 | 90618342 |
| Ascites | 953.24 | 47.32 | 265 | 4990 | 47475 | 90575717 |
| Abdominal distension | 372.17 | 47.32 | 171 | 5084 | 130430 | 90492762 |
| Ovarian haemorrhage | 249.78 | 47.32 | 39 | 5216 | 372 | 90622820 |
| Maternal exposure before pregnancy | 244.63 | 47.32 | 67 | 5188 | 11146 | 90612046 |
| Pelvic fluid collection | 206.46 | 47.32 | 38 | 5217 | 1021 | 90622171 |
| Ovarian enlargement | 166.16 | 47.32 | 29 | 5226 | 571 | 90622621 |
| Abdominal pain | 161.87 | 47.32 | 153 | 5102 | 395568 | 90227624 |
| Adnexal torsion | 155.91 | 47.32 | 27 | 5228 | 507 | 90622685 |
| Pleural effusion | 143.28 | 47.32 | 86 | 5169 | 111905 | 90511287 |
| Haemoperitoneum | 135.06 | 47.32 | 33 | 5222 | 3495 | 90619697 |
| Tension | 118.66 | 47.32 | 30 | 5225 | 3652 | 90619540 |
| Abortion spontaneous | 117.60 | 47.32 | 59 | 5196 | 53997 | 90569195 |
| Inappropriate schedule of product administration | 115.77 | 47.32 | 84 | 5171 | 149849 | 90473343 |
| Abdominal pain lower | 106.32 | 47.32 | 46 | 5209 | 30131 | 90593061 |
| Intra-abdominal haemorrhage | 92.30 | 47.32 | 23 | 5232 | 2639 | 90620553 |
| Ectopic pregnancy | 78.27 | 47.32 | 21 | 5234 | 3220 | 90619972 |
| Multiple pregnancy | 76.45 | 47.32 | 11 | 5244 | 56 | 90623136 |
| Effusion | 72.41 | 47.32 | 18 | 5237 | 2044 | 90621148 |
| Pelvic pain | 62.68 | 47.32 | 26 | 5229 | 15331 | 90607861 |
| Infrequent bowel movements | 57.11 | 47.32 | 14 | 5241 | 1500 | 90621692 |
| Blood oestrogen increased | 56.44 | 47.32 | 10 | 5245 | 215 | 90622977 |
| Ovarian cyst ruptured | 52.62 | 47.32 | 13 | 5242 | 1439 | 90621753 |
| Poor response to ovulation induction | 52.54 | 47.32 | 6 | 5249 | 0 | 90623192 |
| Dyspnoea | 50.96 | 47.32 | 138 | 5117 | 880817 | 89742375 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Product packaging quantity issue | 229.25 | 73.04 | 35 | 563 | 1318 | 42619419 |
| No adverse event | 187.62 | 73.04 | 52 | 546 | 38969 | 42581768 |
| Product dose omission issue | 161.71 | 73.04 | 65 | 533 | 154300 | 42466437 |
| Circumstance or information capable of leading to medication error | 75.93 | 73.04 | 15 | 583 | 2513 | 42618224 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ovarian hyperstimulation syndrome | 6677.20 | 46.26 | 905 | 3848 | 4455 | 110580091 |
| Ascites | 799.16 | 46.26 | 251 | 4502 | 92557 | 110491989 |
| Abdominal distension | 336.01 | 46.26 | 159 | 4594 | 174944 | 110409602 |
| Ovarian haemorrhage | 251.01 | 46.26 | 37 | 4716 | 323 | 110584223 |
| Pelvic fluid collection | 218.78 | 46.26 | 38 | 4715 | 995 | 110583551 |
| Ovarian enlargement | 178.35 | 46.26 | 28 | 4725 | 384 | 110584162 |
| Abdominal pain | 163.36 | 46.26 | 151 | 4602 | 512838 | 110071708 |
| Adnexal torsion | 162.21 | 46.26 | 26 | 4727 | 410 | 110584136 |
| Maternal exposure before pregnancy | 154.59 | 46.26 | 40 | 4713 | 7225 | 110577321 |
| Pleural effusion | 120.86 | 46.26 | 82 | 4671 | 177627 | 110406919 |
| Tension | 118.01 | 46.26 | 30 | 4723 | 5048 | 110579498 |
| Haemoperitoneum | 111.39 | 46.26 | 29 | 4724 | 5359 | 110579187 |
| Abdominal pain lower | 93.69 | 46.26 | 41 | 4712 | 37242 | 110547304 |
| Multiple pregnancy | 74.67 | 46.26 | 10 | 4743 | 39 | 110584507 |
| Effusion | 72.57 | 46.26 | 18 | 4735 | 2739 | 110581807 |
| Intra-abdominal haemorrhage | 69.61 | 46.26 | 20 | 4733 | 5322 | 110579224 |
| Blood oestrogen increased | 67.18 | 46.26 | 11 | 4742 | 199 | 110584347 |
| Product packaging quantity issue | 58.88 | 46.26 | 14 | 4739 | 1785 | 110582761 |
| Pelvic pain | 58.55 | 46.26 | 23 | 4730 | 15919 | 110568627 |
| Dyspnoea | 58.51 | 46.26 | 139 | 4614 | 1106733 | 109477813 |
| Ovarian cyst ruptured | 58.31 | 46.26 | 13 | 4740 | 1248 | 110583298 |
| Ovarian cyst | 47.33 | 46.26 | 19 | 4734 | 13911 | 110570635 |
| Tubo-ovarian abscess | 47.06 | 46.26 | 9 | 4744 | 405 | 110584141 |
None
| Source | Code | Description |
|---|---|---|
| ATC | G03GA08 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM GONADOTROPINS AND OTHER OVULATION STIMULANTS Gonadotropins |
| FDA CS | M0009540 | Gonadotropins |
| FDA EPC | N0000175838 | Gonadotropin |
| CHEBI has role | CHEBI:74518 | anti-obesity agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Ulcerative colitis | indication | 64766004 | DOID:8577 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Lutropin-choriogonadotropic hormone receptor | GPCR | AGONIST | CHEMBL | CHEMBL |
| ID | Source |
|---|---|
| 6413W06WR3 | UNII |
| 4021245 | VANDF |
| C0017963 | UMLSCUI |
| CHEBI:749511 | CHEBI |
| CHEMBL1201464 | ChEMBL_ID |
| D03478 | KEGG_DRUG |
| DB00097 | DRUGBANK_ID |
| 7473 | INN_ID |
| C412828 | MESH_SUPPLEMENTAL_RECORD_UI |
| 283550 | RXNORM |
| 15777 | MMSL |
| 38355 | MMSL |
| 009029 | NDDF |
| 129494006 | SNOMEDCT_US |
| 391878002 | SNOMEDCT_US |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Ovidrel | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44087-1150 | INJECTION, SOLUTION | 250 ug | SUBCUTANEOUS | BLA | 23 sections |